Potential Risks Despite the potential benefits, there are concerns regarding the use of GLP-1 agonists in individuals with pre-existing bone conditions: Fracture Risk: Some studies have raised questions about whether long-term use of GLP-1RAs might be associated with an increased risk of fractures
Both reached Canadian pharmacies in the type 2 diabetes indication (Ozempic-equivalent) in May 2026, followed by a 2.4 mg weight-management generic in late 2026 or early 2027, with generic cash prices expected to ease further as more manufacturers launch and several provinces review the generic for public-plan coverage [3]
You see, the liver processes everything from medications to environmental exposures to byproducts of normal digestion
Neuroprotection by solanesol against ethidium bromide-induced multiple sclerosis-like neurobehavioral, molecular, and neurochemical alterations in experimental rats
This maladaptive process is typically accompanied by progressive deterioration of cardiac performance, ultimately predisposing patients to adverse events including arrhythmia and heart failure
Yes, in moderation